Companies /Healthcare

Ironwood Pharmaceuticals Inc - Class A

NASDAQ: IRWD Drug Manufacturers - Specialty & Generic
$4.83
▼ $0.02 (−0.41%) today
Markets closed · 1:13pm ET

IRWD at a Glance

Valuation
Market cap
$799.6M
P/E ratio
5.4
Profitability
Revenue (TTM)
$400.3M
Profit margin
37.4%
EPS (TTM)
$0.89
Price
52-week range
$3 – $6
Street target
$6.17

Headquartered in Boston, MA Fiscal year ends December NASDAQ: IRWD ironwoodpharma.com

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals is a biotechnology company that develops and commercializes therapies for gastrointestinal (GI) and rare diseases.

Its revenue comes almost entirely from LINZESS (linaclotide), a once-daily GC-C agonist capsule. LINZESS is the #1 prescribed U.S. brand for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC), and it is also approved for pediatric functional constipation.

Ironwood co-develops and co-commercializes LINZESS in the U.S. with AbbVie and shares U.S. brand profits and losses equally. It records its 50% share of net profit as collaboration revenue. Royalties and other revenue come from partners outside the U.S.:
- AbbVie markets linaclotide as CONSTELLA in Europe and holds rights in other territories.
- Astellas markets LINZESS in Japan.
- Grand Life Sciences is the partner in China.

Ironwood's main pipeline asset is apraglutide, an investigational once-weekly, long-acting synthetic GLP-2 analog obtained through the VectivBio acquisition. It is in the global confirmatory STARS-2 Phase 3 trial for adults with short bowel syndrome who depend on parenteral support, with a regulatory filing targeted for 2029.

The company is funded by LINZESS cash flows and a revolving credit facility, and it carries a stockholders' deficit. Leadership will transition from CEO Tom McCourt to Tammi Gaskins on January 1, 2027. Updated

Latest Activity

IRWDIronwood Pharmaceuticals
Q3 2026
EPS
$0.36
est $0.31+16.1%
Revenue
$133M
est $122M+9.4%

A $623 million company just raised full-year guidance for the second straight quarter, lifting LINZESS U.S. net sales to $1.20 billion to $1.25 billion. Operating cash flow nearly tripled to $130.8 million.

Quarterly EPS — reported vs estimate

IRWD Coverage

11:38am ET
Health and Healthcare

Ironwood Pharma Muted Despite FDA Approval

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) shares remained relatively muted on Monday after the firm announced a key U.S. Food and Drug Administration (FDA) approval for its gout treatment duzallo. The firm expects…

Chris Lange

Frequently Asked Questions

What does Ironwood Pharmaceuticals do?

Ironwood Pharmaceuticals is a biotechnology company that develops and commercializes therapies for gastrointestinal (GI) and rare diseases. Its revenue comes almost entirely from LINZESS (linaclotide), a once-daily GC-C agonist capsule.

What is the IRWD stock price target?

The Wall Street consensus 12-month price target for IRWD is $6.17.